SCHEMBL4175286

SCHEMBL4175286

CCc1ccccc1Oc1c(Cl)cccc1C#N

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 0.48
SLC22A12 Q96S37 3/20 0.42
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
NPBWR1 P48145 1/20 0.40
CXCL8 P10145 1/20 0.39
LMNA P02545 1/20 0.39
ADRB2 P07550 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TSHR P16473 2/20 0.38
ALDH1A1 P00352 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2845418 0.78 SLC6A4 (0.43) SLC6A2SLC6A4SLC6A3CXCL8NPSR1
SCHEMBL4181484 0.76 AR (0.68) ARSLC22A12SLC6A2SLC6A4SLC6A3
SCHEMBL6177741 0.75 AR (0.51) ARSLC22A12SLC6A2LMNAADRB2
SCHEMBL11430105 0.74 SLC6A2 (0.66) SLC6A2SLC6A4SLC6A3CXCL8ALDH1A1
SCHEMBL30602897 0.73 L3MBTL1 (0.48) ARSLC22A12TSHRALDH1A1GAA
SCHEMBL27937348 0.72 KDM4E (0.42) ARSLC22A12SLC6A2LMNAADRB2
SCHEMBL20231243 0.72 TSHR (0.42) ARNPBWR1TSHRALDH1A1NPSR1
SCHEMBL4178705 0.71 AR (0.68) ARSLC6A2SLC6A4SLC6A3
SCHEMBL7103488 0.71 XDH (0.43) ARTSHR
SCHEMBL27659861 0.71 L3MBTL1 (0.44) SLC22A12NPBWR1LMNATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105349-A1 ANDROGEN MODULATORS WARNER-LAMBERT COMPANY LLC (US) 2009-04-23 US claimed
EP-1781280-A2 ANDROGEN MODULATORS Warner-Lambert Company LLC (US) 2007-05-09 EP claimed
WO-2006018723-A2 ANDROGEN MODULATORS WARNER-LAMBERT COMPANY LLC (US) 2006-02-23 WO claimed
US-20090105349-A1 ANDROGEN MODULATORS WARNER-LAMBERT COMPANY LLC (US) 2009-04-23 US disclosed
EP-1781280-A2 ANDROGEN MODULATORS Warner-Lambert Company LLC (US) 2007-05-09 EP disclosed
WO-2006018723-A2 ANDROGEN MODULATORS WARNER-LAMBERT COMPANY LLC (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105349-A1 ANDROGEN MODULATORS AR, NR5A1, SHBG AR 1/4885SLC22A12 3958/4885SLC6A2 3445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.